PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

• Status: Completed
• Trial end date: 2020-10-24
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: LCZ 696; Valsartan

Criteria

Inclusion Criteria:

• Receiving sacubitril/valsartan as per the Canadian product label and treatment initiation within the last 3 months

• Able to communicate with investigator

Exclusion Criteria:

• Participation in a clinical trial of an investigational drug, concurrently, or within the last 30 days

• Presence of any condition that in the opinion of the investigator, prohibits patient from participating in the trial